Omada Health (NASDAQ:OMDA) CEO Sells $321,091.02 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,942 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $24.81, for a total transaction of $321,091.02. Following the sale, the chief executive officer owned 411,861 shares in the company, valued at approximately $10,218,271.41. This trade represents a 3.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Omada Health Stock Performance

Shares of NASDAQ:OMDA opened at $24.37 on Friday. Omada Health, Inc. has a 52-week low of $10.28 and a 52-week high of $26.92. The firm has a fifty day moving average of $20.87 and a 200 day moving average of $16.43. The firm has a market capitalization of $1.49 billion, a PE ratio of 487.40 and a beta of 1.73.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. Omada Health had a return on equity of 2.67% and a net margin of 1.39%.The business had revenue of $87.83 million for the quarter, compared to the consensus estimate of $80.93 million. On average, sell-side analysts forecast that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on OMDA. Morgan Stanley reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Omada Health in a research note on Monday, June 22nd. Wells Fargo & Company boosted their price objective on shares of Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. BTIG Research upped their price objective on shares of Omada Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. Evercore reaffirmed an “outperform” rating and set a $20.00 target price on shares of Omada Health in a report on Friday, May 8th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $24.00 target price on shares of Omada Health in a research report on Friday, August 7th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $25.75.

Institutional Trading of Omada Health

A number of institutional investors have recently made changes to their positions in OMDA. Raymond James Financial Inc. bought a new position in shares of Omada Health in the second quarter worth approximately $32,000. Bellevue Group AG raised its holdings in Omada Health by 0.7% during the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after buying an additional 1,791 shares during the last quarter. Quarry LP bought a new stake in Omada Health during the 4th quarter valued at $29,000. Barclays PLC boosted its position in Omada Health by 14.6% during the 4th quarter. Barclays PLC now owns 14,850 shares of the company’s stock valued at $234,000 after buying an additional 1,888 shares during the period. Finally, TD Waterhouse Canada Inc. bought a new stake in Omada Health in the 4th quarter worth $32,000.

Omada Health News Roundup

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q2 results exceeded expectations. Omada reported adjusted earnings of $0.08 per share, compared with analysts’ expectation of a $0.02 loss, while revenue of approximately $87.8 million topped the $80.9 million consensus estimate. The results suggest growth in its digital chronic-care platform is increasingly converting into profitability. Omada Health Q2 earnings analysis
• Positive Sentiment: Several analysts raised their targets. Robert W. Baird lifted its price target from $15 to $25, while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG. The broader analyst consensus remains “Moderate Buy,” with an average target around $25.67–$25.75.
• Positive Sentiment: Institutional ownership increased. Perceptive Advisors and BlackRock reportedly initiated positions, Millennium Management expanded its stake, and Versant Capital Management increased its holdings by more than 300%. These moves may reinforce investor confidence in Omada’s growth outlook.
• Neutral Sentiment: Baird’s neutral stance highlights limited near-term upside. Its $25 target is only modestly above the recent trading level, suggesting the earnings beat and growth prospects may already be substantially reflected in the stock price.
• Negative Sentiment: Multiple senior executives sold shares. CEO Sean Duffy sold 8,628 shares, CFO Steven Cook sold 16,842 shares across two transactions, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. Although these sales may reflect personal liquidity or compensation planning, concentrated selling near $25 can weigh on sentiment. Omada Health insider trading report
• Negative Sentiment: Valuation risk remains elevated. Omada’s market capitalization is approximately $1.5 billion, while its reported price-to-earnings ratio is above 475. With the shares close to their 52-week high, any slowdown in revenue growth or profitability could prompt profit-taking.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.